Tag Archives: Tenofovir

Clinical Effect of Moringa oleifera on Body mass index,Triglyceride and High density lipoprotein in Subjects Taken Tenofovir Combination Regimen (Published)

Antiretroviral drugs can have adverse effects. Most are manageable, but some can be serious. The aim of this clinical study is to evaluate the potential benefits of taking Moringa oleifera on body mass index (BMI), blood triglyceride and High density lipoprotein (HDL) level in patient taking Tenofovir/Lamivudine/efavirenz (TLE) combination. The study was designed as a Longitudinal Randomized Comparative Trial (LRCT) involving 140 HIV adult subjects (56 males, 84 females) who have been on Tenofovir/Lamivudine/efavirenz (300/300/600mg) TLE combination for at least 6 months prior to the study. They were recruited from a Teaching Hospital in Nigeria. Moringa oleifera capsules (200mg) were administered by the subjects to be used beginning from the first day of visit 0, through visit 1 (after four weeks) and 2 (after 12 weeks). Blood samples of subjects were collected at each visit (visit 0, 1 and 2) and analyzed for triglyceride and HDL level.There was no significant reduction in serum HDL level (P<0.01) of subjects in visit 1 but there was significant (P<0.01) increase on visit 2 when compared to visit 0. There was also significant improvement in blood triglyceride level (P<0.01) in visit 1 and 2 compared to visit 0 of tenofovir/Lamivudine/Efavirenz (TLE) moringa combination. Results from the study suggests that Moringa oleifera may be useful in improving triglyceride and cholesterol level of patients receiving TLE combination.

Keywords: Moringa oleifera, Tenofovir, blood, glucose, triglyceride

Clinical Effect of Moringa oleifera on Body mass index, Triglyceride and High density lipoprotein in Subjects Taken Tenofovir Combination Regimen (Published)

Antiretroviral drugs can have adverse effects. Most are manageable, but some can be serious. Moringa oleifera is a readily available plant with several use. The aim of this clinical study is to evaluate the potential benefits of taking Moringa oleifera on body mass index (BMI), blood triglyceride and High density lipoprotein (HDL) level in patient taking Tenofovir/Lamivudine/efavirenz (TLE) combination. The study was designed as a Longitudinal Randomized Comparative Trial (LRCT) involving 140 HIV adult subjects (56 males, 84 females) who have been on Tenofovir/Lamivudine/efavirenz (300/300/600mg) TLE combination for at least 6 months prior to the study. They were recruited from a Teaching Hospital in Nigeria. Moringa oleifera capsules (200mg) were administered by the subjects to be used beginning from the first day of visit 0, through visit 1 (after four weeks) and 2 (after 12 weeks). Blood samples of subjects were collected at each visit (visit 0, 1 and 2) and analyzed for triglyceride and HDL level. There was no significant reduction in serum HDL level (P<0.01) of subjects in visit 1 but there was significant (P<0.01) increase on visit 2 when compared to visit 0. There was also significant improvement in blood triglyceride level (P<0.01) in visit 1 and 2 compared to visit 0 of tenofovir/Lamivudine/Efavirenz (TLE) moringa combination Results from the study suggests that Moringa oleifera may be useful in improving triglyceride and cholesterol level of patients receiving TLE combination.

Citation: Joseph Opeyemi Tosin, Sabastine Aliyu Zubairu, Joseph Oyepata Simeon (2021) Clinical Effect of Moringa oleifera on Body mass index, Triglyceride and High density lipoprotein in Subjects Taken Tenofovir Combination Regimen, European Journal of Biology and Medical Science Research, Vol.9, No.4, pp.6-19

Keywords: Moringa oleifera, Tenofovir, blood, glucose, triglyceride

Reliability of Some Selected Novel Markers in Detecting Early Renal Dysfunction in HIV Positive Patients on TDF Regimen: A Nigerian Study (Published)

This study evaluated the predictability of novel biomarkers (Urine Cystatin C, NGAL and Albumin) in detecting early renal dysfunction. About 140 patients (53 (37.9 %) male and 87 (62.1%) female) who attends ARV clinic at the University’s Teaching Hospital, Port Harcourt were included in the study. The study was designed in 3 phase to include Visit 0, 1 and 2 which lasted for about 12weeks (3months). Visit 1 was 4weeks from visit 0 and Visit 2 was 8 weeks from Visit 1. Laboratory assessment was carried out on samples collected from the patients, Albumin was 0.90±0.56, 1.36±0.89, and 1.36±0.94; Urine Creatinine was 479±1.90, 489.06±445.09 and 514.85±595.55; Urine Total Protein was 15.04±26.73 9.50±5.07 and 6.53±3.84; while NGAL was, 1902.51±902.59, 1941.48±743.60 and 4881.60±2792.01and Cystatin C was 889.70±1201.04, 1062.38±1165.38 and 1577.92±506.61 for Visit 0, 1 and 2 respectively. Significant difference was observed in the measured parameters across all Visits from 1st visit to end of the study.  The differences observed between the markers across all visits were significant. Using differential reliability test, NGAL has 241.67% better chance of predicting renal dysfunction compared to Cystatin C, while Cystatin C has 166.67% better chance of predicting renal dysfunction compared to albumin, while NGAL also has 811.1% better chance of predicting renal impairment as compared to albumin. However, creatinine clearance did not pick up renal dysfunction. This study is therefore recommended to Physicians in other to help in diagnosing early renal dysfunction in HIV patients, especially those on tenofovir (TDF) based ARV regime which has been proven to cause renal dysfunction.

Keywords: Biomarkers, Cystatin C and Albumin, HIV, NGAL, Tenofovir

Evaluating the Effect of Moringa (K Formula Dietary Supplement) On Renal Function among HIV Positive Patients on TDF Regimen: A Longitudinal Study of Nigerians (Published)

This study evaluated the effect of Moringa on the renal function of HIV positive patients. It was a time dependent comparative pilot study involving 140 patients (53 (37.9 %) male and 87 (62.1%) female) in the sampled population, who attends ARV clinic at the University’s Teaching Hospital, Port Harcourt. The study was a 3 phases design to include Visit 0, 1 and 2 which lasted for about 12weeks (3months). The subjects were divided into two experimental groups (those receiving tenofovir and moringa and those receiving tenofovir without moringa supplementation). For the moringa group at visit 0, 1 and 2 respectively, the following values were obtained (Urine phosphate was 16.3711.84, 12.798.37 and 18.356.29; Urine Albumin was 2.001.41, 1.290.96 and 1.132.54; Urine Creatinine was 125.682.01, 418.53225.54 and 766.211030.82; Uric acid was 326.4387.45, 289.8782.50 and 239.3867.36; Urine Total Protein was 7.625.06; 19.8542.94 and 8.453.85. Significant differences were seen in the measured parameters at Visit 0, 1 and 2. However in the non moringa group, Urine phosphate was 16.93±12.53, 17.49±9.33 and 18.94±6.77; Urine Albumin was 0.90±0.56, 1.36±0.89, and 1.36±0.94; Urine Creatinine was 479±1.90, 489.06±445.09 and 514.85±595.55; Uric acid was 317.81±72.78, 311.79±65.55 and 259.56±84.04; Urine Total Protein was 15.04±26.73 9.50±5.07 and 6.53±3.84; for Visit 0, 1 and 2. Significant difference was observed in the measured parameters across all Visits from baseline to end of study.  However differences were generally higher in the control, compared to the experimental groups. Finding therefore shows that moringa improved renal function slightly in HIV positive subjects, while sex was also observed to play a role. The study is therefore recommended to Physicians and care givers in other to help improve the health and wellbeing of HIV patients, especially those on tenofovir (TDF) based ARV regimen.

Keywords: HIV, Moringa, Renal Dysfunction, Tenofovir

Reliability of Some Selected Novel Markers in Detecting Early Renal Dysfunction in HIV Positive Patients on TDF Regimen: A Nigerian Study (Published)

This study evaluated the predictability of novel biomarkers (Urine Cystatin C, NGAL and Albumin) in detecting early renal dysfunction. About 140 patients (53 (37.9 %) male and 87 (62.1%) female) who attends ARV clinic at the University’s Teaching Hospital, Port Harcourt were included in the study. The study was designed in 3 phase to include Visit 0, 1 and 2 which lasted for about 12weeks (3months). Visit 1 was 4weeks from visit 0 and Visit 2 was 8 weeks from Visit 1. Laboratory assessment was carried out on samples collected from the patients, Albumin was 0.90±0.56, 1.36±0.89, and 1.36±0.94; Urine Creatinine was 479±1.90, 489.06±445.09 and 514.85±595.55; Urine Total Protein was 15.04±26.73 9.50±5.07 and 6.53±3.84; while NGAL was, 1902.51±902.59, 1941.48±743.60 and 4881.60±2792.01and Cystatin C was 889.70±1201.04, 1062.38±1165.38 and 1577.92±506.61 for Visit 0, 1 and 2 respectively. Significant difference was observed in the measured parameters across all Visits from 1st visit to end of the study.  The differences observed between the markers across all visits were significant. Using differential reliability test, NGAL has 241.67% better chance of predicting renal dysfunction compared to Cystatin C, while Cystatin C has 166.67% better chance of predicting renal dysfunction compared to albumin, while NGAL also has 811.1% better chance of predicting renal impairment as compared to albumin. However, creatinine clearance did not pick up renal dysfunction. This study is therefore recommended to Physicians in other to help in diagnosing early renal dysfunction in HIV patients, especially those on tenofovir (TDF) based ARV regime which has been proven to cause renal dysfunction.

Keywords: Biomarkers, Cystatin C and Albumin, HIV, NGAL, Tenofovir